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The discovery that not all agonists uniformly activate cellular signaling pathways (biased signaling) has greatly
changed the drug discovery process for agonists and the strategy for treatment of disease with agonists.
Technological advances have enabled complex receptor behaviors to be viewed independently and through these
assays, the bias for an agonist can be quantified. It is predicted that therapeutic phenotypes will be linked, through
translational studies, to quantified scales of bias to guide medicinal chemists in the drug discovery process.Introduction
Agonists constitute a major class of therapeutic drug
and pose special problems with respect to the drug dis-
covery process. Specifically, agonist activity is intimately
tied to the sensitivity of the tissue in which the activity
is measured therefore the obvious measures of agonist
activity (i.e. potency and maximal response) can be
complex and certainly are system dependent. As in most
cases, new therapeutic entities are discovered, optimized
and characterized in test systems, rarely the therapeutic
one. Therefore, system-independent reliable scales to
describe agonist activity are critical in the process of
identifying agonist drug candidates. A pharmacologic
workhorse for the quantification of agonist activity has
been the agonist potency ratio. This tool compares
equal responses via null methods to cancel tissue effects
to yield ratios that depend only on agonist affinity and
efficacy. Since these are unique properties of the mole-
cules, these ratios can be system independent and in-
valuable as predictors of activity in therapeutic systems.
Potency ratios are applicable only when comparing full
agonists and cannot be applied to comparisons of full to
partial agonist activity. However, other techniques that
identify system independent measures of agonist activity
can be estimated through tools such as the Black/Leff
operational model; this characterizes the affinity (as KA
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reproduction in any medium, provided the oragonist-receptor complex) and τ (where τ is the agonist
intrinsic efficacy and sensitivity to agonist of the tissue-
vide infra) [1]. Thus estimates of τ and KA become the
system independent measures of agonism.
The use of these techniques to compare whole cell
activity for drug discovery depends on an important
assumption, namely that the function linking receptor
occupancy and tissue response be monotonic (i.e. that
there be only one value of y (response) for every x
(concentration of drug)). Under these circumstances,
ratios of activity seen for whole cell response should
accurately mirror ratios of the initial stimulus that the
agonist gives to the system (the molecular properties
of affinity and efficacy). A further basic assumption in
the use of whole cell relative activities of agonism is
that all agonists stabilize a common active state of the
receptor to generate response. In the absence of evi-
dence to the contrary, this is the most parsimonious
model of agonism and it has been operative for 50 years
in pharmacology. However, over the past 20 years there
have been a number of papers published that suggest that
stimulus–response coupling is more complex [2-9] and
that whole cell potency ratios for agonists can be variable.
The basis for these ideas stem from examples where mul-
tiple responses are measured from a single receptor type
showing that some agonists produce pleiotropic responses
and others do not. As a preface to the discussion of the
mechanism by which this can occur at the receptor level,
it is useful to consider a subset of these examples where
agonists demonstrate apparently selective pathway agon-
ism because of the efficiency of stimulus-coupling in the
cell.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The efficiency of coupling of various cellular pathways is
probably tailored to the needs of the cell. For example, β-
adrenoceptor activation in the rat atrium produces myocar-
dial inotropy (increase force of isometric contraction) and
lusitropy (increased rate of relaxation) and it can be seen
that dose–response curves for lusitropic effects are shifted
by a factor of three to the left of those for inotropic effects
[10]-see Figure 1. This would be consistent with a condition
whereby lusitropy requires a lower level of cyclic AMP ele-
vation than does inotropy. The relevant point to this dis-
cussion is that this cellular bias with respect to signaling is
a property of the tissue (not any specific difference in the
efficacy of the agonists) and thus it is a condition that will
be true for all agonists in the tissue; these effects will be re-
ferred to as ‘system bias’. Differences in the sensitivity of
pathways becomes even more pronounced when different
assays are compared. For example, it is generally true that
enzyme complementation assays for β-arrestin effects are
considerably less sensitive than second messenger assays
such as cyclic AMP elevation. This can lead to a number of
apparently ‘selective’ agonist effects whereby weak agonists
can produce activation of only the most efficiently coupledFigure 1 Effects of isoproterenol and pirbuterol on rat atrial isometric
relaxation (lusitropy; open circles). The concentration-response curve fo
indicating a difference in the intrinsic coupling efficiencies of the β-adrenopathway; this effect will be referred to as ‘observation bias’.
These ‘strength of signal’ profiles are not necessarily exam-
ples of ligand bias and should not be considered as such.
Every pharmacologic experiment concerning agonism
will be subject to system and observation bias but these
effects can be cancelled through null procedures whereby
agonists are compared to each other within a given signal-
ing pathway. In addition, these types of bias generally are
not useful therapeutically since all agonists are subject to
their effects and the extent of the effect is linked to the na-
ture of the system (i.e. species, organ, experimental condi-
tions etc.). True ligand bias is superimposed upon these
effects to produce a ligand-specific agonism that will trans-
late to in vivo systems and give phenotypically unique pro-
files of agonism.
Ligand directed signaling
Within the time period where variance of experimental
data from theoretical prediction were reported there began
to appear cases where a simple strength of signal mechan-
ism could not account for differences in agonist response.
It should be noted that the important advancement in
pharmacology that allowed these effects to be studied wascontraction peak height (inotropy; filled circles) and rate of
r lusitropy is shifted 3-fold to the left of the curve for inotropy
ceptor to these two physiological processes. Data redrawn from [10].
Figure 2 Molecular mechanism for agonist-directed biased
signaling. Agonist A stabilizes a conformation of the receptor that
preferably activates pathway 1 while agonist B stabilizes a receptor
conformation that preferably activates pathway 2.
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behavior. Thus, for example, instead of inferring effects on
receptor desensitization and internalization from the dis-
appearance of agonist response, these effects could be
viewed independently with imaging assays. When this was
done it was seen that internalization did not always paral-
lel agonism and in fact, could be shown to be an inde-
pendent phenomenon [11,12].
The major type of observation to suggest that agonists
possessed the innate property of controlling cellular
pathway stimulation is the demonstration that the rela-
tive potencies of agonists actually reverse order when
two pathways controlled by the same receptor are
observed. For example, in LLC-PK1 cells transfected
with PACAP receptors the relative potencies of the
PACAP analogues PACAP1-27 and PACAP1-38 for in-
creasing cellular cyclic AMP and inositol phosphate
were determined. It was observed that the two agonists
reverse their relative order of potency for the two signal-
ing pathways mediated by the same receptor (i.e. the rela-
tive potency for cyclic AMP is PACAP1-27>PACAP1-38
and PACAP1-27<PACAP1-38 for inositol phosphate pro-
duction) [13]. Similarly, the relative potency of Eel and Por-
cine calcitonin reversed order when HEK cells were
enriched with Gαs through transduction [14]. In these cases,
a strength of signal mechanism cannot account for the dif-
ference in potency ratio and another hypothesis is needed.
This type of divergent data for relative agonist potency
clearly suggested that the binding of different agonists
leads to the production of different receptor species with
varying preference for signaling proteins, i.e. different
agonists produce different receptor active states; the first
proposal of this mechanism labeled the effect ‘stimulus-
trafficking’ [15]-see Figure 2. Subsequently, a number of
pharmacologic approaches utilizing cellular agonist
response were used and data consistent with ligand-
specific receptor active state formation were reported
(for reviews see [16-20]). Notably, studies with dopamine
agonists [3,21] and serotonin [22] clearly showed the effect;
the most common terms utilized to describe these effects
over this period were agonist ‘bias’ or ‘functional selectivity’.
In addition to cellular pharmacologic studies, agonist for-
mation of different receptor states has been shown through
chemical and structural studies with a number of techni-
ques (see [23-38]).For example, 19 F-NMR studies show the
adoption of different β2-adrenoceptor conformations with
binding of different ligands [39]. Therefore, in addition to
system bias for any two pathways in the cell (or any two
functional response readouts) a ligand bias can be imposed.
How signaling bias alters ligand pharmacology
True ligand bias denotes that the chemical structure of
the molecule has coded within it the information needed
to route stimulus to selected signaling proteins in thecell; this is done through the stabilization of a unique re-
ceptor conformations. When controlled through medi-
cinal chemistry, this phenomenon has the potential to
improve the signaling profiles of agonists and antago-
nists for therapeutic benefit. The key to achieving this
type of control is to have assays that can detect and
quantify selective pathway signaling. For example,
in vitro assays that measure second messenger produc-
tion (eg. cyclic AMP from Gαs activation of adenylate
cyclase) and the association of receptor with β-arrestin
(Bioluminescent Resonance Energy Transfer, BRET) can
be used to separately assess the ability of a ligand to acti-
vate the pathways. The other requirement is a quantita-
tive scale by which pharmacologists and medicinal
chemists can gauge the effect of changing molecular
structure on the bias of a given chemical scaffold. The
key to such a scale is that it be intimately associated with
the specific pathway being assessed, i.e. as discussed pre-
viously, parameters that characterize the receptor species
interacting with the signaling molecules must be deter-
mined. As a preface to the discussion of system inde-
pendent parameters of agonism, it is useful to describe
the theoretical context of the model for agonism, namely
the Black/Leff operational model [1]. In this model, re-
sponse is controlled by the affinity of the agonist
(denoted as KA
-1 where KA is the equilibrium dissociation
constant of the agonist-receptor complex) and efficacy
denoted by τ where τ= [Rt] (membrane receptor density)
divided by KE, the virtual Michaelis-Menten constant for
the interaction of the agonist-bound receptor as it inter-
acts with the cell where the cell is defined as a virtual
enzyme. The efficacy term τ thus describes both the
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molecule to induce response) and the sensitivity of the
system to return response (number of responding units
[receptors] and the efficiency of receptor coupling to
stimulus–response mechanisms in the cell). Response is
thus given by the equation:
Response ¼ A½ 
nτnEm
A½ nτn þ A½  þ KAð Þn ð1Þ
where n is the Hill coefficient for the agonist
concentration-response curve. Since receptors are allo-
steric proteins, these parameters must involve the con-
stants that define the interactions of the agonist (termed
the allosteric modulator of the effect) and the guest (in
this case the signaling molecule) with the receptor. The
former parameter is the affinity of the agonist for the re-
ceptor (KA) which, for allosteric proteins such as recep-
tors, is a conditional parameter. Affinity must be
included in the parameter estimate since allosteric
mechanisms dictate that KA will be different for the
agonist-receptor pair for different signaling molecules.
This has been shown in structural and binding studies
for β2-adrenoceptors [40], κ-opioid receptors [41], and
ghrelin receptors [42]. The parameter τ is a characteris-
tic ‘efficacy’ of the resulting agonist-receptor complex.
Therefore the minimal theoretically sound unit to de-
note agonist power to produce activation of any given
cellular pathway is τ/KA (generally utilized as the log
normal parameter Log (τ/KA)). While this parameter can
be estimated by fitting data to equation 1, it also can be
shown that for systems where n = 1, Log (τ/KA) values
reduce to Log (RA) values where RA refers to ‘Receptor
Activity’ indices defined by Ehlert and colleagues [43] as
(maximal response)/EC50 for agonism (where EC50 is the
molar concentration producing 50 % maximal response
to the agonist). Log (RA) values are the most simple
index of agonism and take into account both the sensi-
tivity of the system and the intrinsic efficacy of the agon-
ist. Therefore, the relative Log (τ/KA) (or for n = 1 cases
Log (RA)) values can be evaluated for a series of agonists
in a given pathway to rank the relative intrinsic efficacy
of the agonists for that pathway. Comparison to the same
reference agonist (usually the natural endogenous agon-
ist) for different pathways can then be used to compare
the relative power of the agonists to activate different
pathways [44]. Theoretically, providing the log (τ/KA)
values represent direct measurement of modulator
(agonist)-conduit (receptor)-guest (signaling pathway
complexes, they will be system independent measures of
agonism [16,44]. Of course where response is measured
from points beyond this complex (i.e. where the cell
mixes and matches components of response), even Log(τ/KA) values become system dependent and less useful
as measures of agonist bias.
Therapeutic implications of biased signaling
The realization that the signaling profiles of agonists may
be subject to modification has led to an explosion of pro-
posals in the literature for improved agonists (and antago-
nists). These are based on data to show that some but not
all signaling produced by agonists is beneficial to the host
organ. For instance, opioids are valuable analgesics but also
can produce respiratory depression. Insofar as respiratory de-
pression can be linked to activation of β-arrestin [45]),
an opioid agonist that stimulates opioid pathways with-
out promoting receptor/β-arrestin interaction would be
predicted to be a superior therapy [46-48]. Treatment
with synthetic orthosteric agonists also precludes receptor
occupancy by the endogenous agonist and this becomes an
important aspect of the in vivo profile of biased ligands. For
instance, in heart failure, blockade of angiotensin
receptors precludes damaging angiotensin-mediated
vasoconstriction. Treatment with a biased angiotensin
antagonist such as TRV120027; Sar-Arg-Val-Tyr-Ile-
His-Pro-D-Ala-OH blocks angiotensin but also pro-
motes beneficial effects of β-arrestin activation (stimula-
tion of p42/44 mitogen-activated protein kinase, Src, and
endothelial nitric-oxide synthase phosphorylation ) and it
is predicted that this will lead to a therapeutic advantage
[49-53]. Initial data support this conclusion. In rats, block-
ade of endogenous angiotensin with conventional angio-
tensin receptor antagonists losartan and telmisartan, leads
to reduced mean arterial pressure but also a decrease in
cardiac performance. In contrast, treatment with
TRV120027 does not decrease but rather increases cardiac
performance and preserves cardiac stroke volume [54].
Similarly, in canine heart failure models TRV120027 pro-
duces cardiac unloading actions but preserves renal func-
tion resulting in a predicted novel strategy for the
treatment of heart failure [55]. It should be noted that
while stabilization of receptor conformation is the most
commonly proposed mechanism for biased ligand effects,
there are potentially other mechanisms that may be opera-
tive, especially with respect to peptide ligands such as
TRV120027. For example, it has been shown that differen-
tial dissociation of the peptides RANTES and AOP-
RANTES from internalized CCR5 receptors causes dif-
ferences in the recycling of receptors back to the cell sur-
face upon internalization. Specifically, the lack of
dissociation of AOP-RANTES from the receptor in the
acidic cytoplasmic environment leads to selective CCR5
endosomal destruction as compared to rapid recycling
with RANTES [56]. In general, biased signaling has been
proposed to be potentially useful in a host of diseases in-
cluding hyperlipidemia (GPR109 receptors [57,58]), heart
failure (β-adrenoceptors [59-61]), some neuropsychiatric/
Figure 3 Impact of agonist-directed stimulus on drug screening. Canonical strategies for high throughput (HTS) screening pass the most
active molecules from the HTS (represented by the dextral tail of the Boltzman distribution representing the best responses in the HTS) into
secondary assays and animal models for further testing. To detect bias in signaling, the active molecules from the HTS are all tested in another
functional assay for another signaling pathway and the most active molecules from that assay pooled with the actives from the HTS for further
testing. The most active molecules in the secondary biased assay often are not the most active in the HTS thus a spectrum of agonists of
differing stimulus bias is tested in animal models.
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hypertension (α2-adrenoceptors [63]), hypothyroidism
(TSR [64]),schizophrenia (dopamine D2 receptors [65-67]),
small-cell lung cancer (GRPR/vasopressin [68]), osteopor-
osis (PTH receptors [69-71]), parkinsonism (dopamine D1
receptors [72]), diabetes (GLP-1 receptors [73]), addiction,
psychosis and depression (5-HT receptors [74,75]).
The consideration of biased signaling in various thera-
peutic areas has been introduced into pharmacology
through various means including theoretical predictions
based on known signaling components of cells and from
studies in gene knockout animals (eg. knockout animals
for β-arrestin-1 [73], β-arrestin-2 [45], p90 ribosomal S6
kinase [76]). However, there are numerous instances
where it still is not yet possible to predict which type of
signaling bias may represent a superior therapy. In these
cases, empirical testing of exemplar molecules in animalmodels is a way forward; these approaches have gener-
ally led to a revolution in the strategy for new drug
discovery.
The impact of signaling bias on drug discovery
When it was assumed that new synthetic ligands
mimic natural endogenous agonists in their quality of
efficacy (the pathways they activated in the cell) and
only differed in the quantity of efficacy they pos-
sessed, a single robust high throughput screen (HTS)
with a suitably sensitive readout of cellular response
was theoretically adequate to find agonists. The dis-
covery that this is not the case and that some ago-
nists activate selected pathways more than others
destroys this assumption. Specifically, a biased agonist
may have weak activity in one assay tailored to meas-
ure a given pathway but a much stronger activity for
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This compels the testing of agonists in multiple path-
ways, an idea at odds with the obvious resource con-
straints of discovery efforts. A fruitful compromise
may be to test the discovered active molecules from
an HTS in other assays designed to measure another
pathway. The testing of screening actives in another
pathway assay would allow the detection of texture in
agonism, i.e. extremes in stimulation profiles could
then be taken into animal models to possibly detect
unique phenotypes in these models-see Figure 3.
The idea that agonists may bias the stimulus they give to
cells is relatively new and as such, may be thought to be
somewhat rare. However, an alternative view which con-
siders that receptors can form numerous states (some ac-
tive with respect to signaling) and that ligands interact
with an ‘ensemble’ of different conformations, predicts a
vast array of bias for different agonists [77-82]. Therefore
the agonist-stabilized ensemble is the result of an array of
conformations stabilized through binding governed by the
affinities of the agonist for particular conformations. This
idea suggests that it would be unlikely that any two ago-
nists would have identical bias with respect to an array of
signaling molecules. Under these circumstances, the high
probability that ligands will not have identical affinities for
a large number of conformations predicts that ligands will
in essence stabilize a nearly unique conformational ensem-
ble and this, in turn, would go on to activate a nearly
unique cadre of stimulus cascades in the cell.Conclusions
The idea that new agonists may well produce receptor
conformations that activate signaling proteins in a biased
manner forces pharmacologists to rethink their concepts
of agonism, i.e. the most potent and efficacious agonist
may not be the best option for therapy. These ideas have
extended the field of target validation beyond target type
to which signaling pathway mediated by that target type is
the relevant ‘target’ for therapy. It will be most interesting
to see if phenotypic signaling determined from in vitro
assays translates to unique therapeutic phenotypes in vivo.
The various discovery efforts with biased ligands presently
in progress should provide answers to this question within
the next few years.
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